Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 9 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 2

2(40.0%)

5Total

N/A(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT07196033Recruiting

Asian Gynecological Brachytherapy Registry in Cervical Cancer

Role: collaborator

NCT06805864Phase 2Not Yet Recruiting

Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma

Role: lead

NCT04707495Not ApplicableCompleted

Treating Depressed Mood With a Smartphone-delivered Positive Word Stimulation for Subthreshold Depression

Role: lead

NCT03007004Phase 2Completed

Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic Sclerosis

Role: lead

NCT00888472Not ApplicableCompleted

Safety and Efficacy of High-dose Leukocytapheresis Using a Large Filter in Refractory Asthma

Role: lead

NCT01009658Not ApplicableCompleted

MSG and Gastrointestinal Motility

Role: lead

NCT00826033Completed

Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer

Role: lead

NCT00698373Completed

Evaluation of Thoracic Tumors With 18F-FMT and 18F-FDG PET-CT A Clinicopathological Study

Role: lead

NCT00671242Completed

Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake

Role: lead

NCT00464282Completed

Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer

Role: lead

NCT00369980Completed

Diagnostic Usefulness of Fluorine-18-α-Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient

Role: lead

All 11 trials loaded